Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) Sees Large Decline in Short Interest

Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) saw a large decline in short interest in the month of September. As of September 30th, there was short interest totaling 67,129 shares, a decline of 66.3% from the September 15th total of 199,073 shares. Based on an average daily trading volume, of 2,041,132 shares, the short-interest ratio is presently 0.0 days. Approximately 0.4% of the company’s shares are short sold.

Hong Kong Pharma Digital Technology Trading Down 3.4%

Shares of NASDAQ:HKPD traded down $0.00 during mid-day trading on Tuesday, hitting $0.10. 43,369 shares of the company traded hands, compared to its average volume of 1,367,734. The firm’s 50 day simple moving average is $0.23 and its 200 day simple moving average is $0.41. Hong Kong Pharma Digital Technology has a 52-week low of $0.10 and a 52-week high of $1.72. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.75 and a current ratio of 3.86.

Hong Kong Pharma Digital Technology (NASDAQ:HKPD) last announced its earnings results on Friday, August 7th. The company reported ($0.04) earnings per share for the quarter. The firm had revenue of $3.15 million for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered Hong Kong Pharma Digital Technology from a “sell (d)” rating to a “sell (e+)” rating in a research report on Thursday, August 13th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

About Hong Kong Pharma Digital Technology

Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.